Neuronetics, Inc. (NASDAQ:STIM) Short Interest Update

Neuronetics, Inc. (NASDAQ:STIM) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 57,700 shares, a decrease of 39.0% from the March 31st total of 94,600 shares. Based on an average daily trading volume, of 170,500 shares, the short-interest ratio is currently 0.3 days.

Insider Buying and Selling

In related news, CFO Stephen Furlong sold 14,710 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $3.51, for a total value of $51,632.10. Following the completion of the sale, the chief financial officer now owns 509,033 shares of the company’s stock, valued at $1,786,705.83. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Neuronetics news, CFO Stephen Furlong sold 14,710 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $3.51, for a total transaction of $51,632.10. Following the completion of the sale, the chief financial officer now directly owns 509,033 shares of the company’s stock, valued at approximately $1,786,705.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP William Andrew Macan sold 15,621 shares of the business’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $3.38, for a total transaction of $52,798.98. Following the sale, the executive vice president now directly owns 417,736 shares of the company’s stock, valued at $1,411,947.68. The disclosure for this sale can be found here. Insiders have sold a total of 150,279 shares of company stock worth $489,167 in the last 90 days. Corporate insiders own 9.80% of the company’s stock.

Hedge Funds Weigh In On Neuronetics

Large investors have recently bought and sold shares of the company. Worth Venture Partners LLC bought a new stake in shares of Neuronetics in the fourth quarter worth $30,000. Fielder Capital Group LLC acquired a new stake in Neuronetics in the 4th quarter valued at $66,000. FNY Investment Advisers LLC bought a new stake in Neuronetics during the 4th quarter worth about $87,000. G2 Investment Partners Management LLC acquired a new position in shares of Neuronetics during the 4th quarter worth about $213,000. Finally, David J Yvars Group boosted its stake in shares of Neuronetics by 108.1% during the 4th quarter. David J Yvars Group now owns 74,930 shares of the company’s stock worth $217,000 after buying an additional 38,930 shares during the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

Neuronetics Trading Up 1.3 %

NASDAQ:STIM traded up $0.04 on Monday, reaching $3.54. The company’s stock had a trading volume of 34,809 shares, compared to its average volume of 178,489. The firm has a market cap of $105.96 million, a PE ratio of -3.31 and a beta of 2.44. The company has a debt-to-equity ratio of 1.73, a quick ratio of 4.33 and a current ratio of 4.73. The business’s 50-day moving average price is $3.93 and its two-hundred day moving average price is $2.84. Neuronetics has a 1-year low of $1.03 and a 1-year high of $5.07.

Neuronetics (NASDAQ:STIM) last posted its earnings results on Tuesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. Neuronetics had a negative return on equity of 72.76% and a negative net margin of 42.31%. The business had revenue of $20.31 million during the quarter, compared to analysts’ expectations of $19.73 million. During the same period in the prior year, the business earned ($0.30) EPS. Equities research analysts anticipate that Neuronetics will post -0.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

STIM has been the topic of a number of recent analyst reports. Piper Sandler restated an “overweight” rating and set a $8.00 target price (up previously from $7.00) on shares of Neuronetics in a report on Wednesday, March 6th. William Blair restated a “market perform” rating on shares of Neuronetics in a report on Tuesday, March 26th.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.